Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2016 | short review | Ausgabe 2/2016 Open Access

memo - Magazine of European Medical Oncology 2/2016

Immune checkpoint blockade in ovarian cancer

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2016
Autoren:
MD PhD Lukas Weiss, MD Florian Huemer, MD Brigitte Mlineritsch, MD Richard Greil

Summary

Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years. Although some reports could evidence a successful induction of anti-tumour T‑cells, in general, these attempts did not translate into clinically significant activity. As has already been shown in other tumour entities, immune checkpoint blockade – mainly antibodies directed against PD-1 and PD-L1 – could possibly become a real “game changer” in ovarian cancer in the future.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2016

memo - Magazine of European Medical Oncology 2/2016 Zur Ausgabe